Insider buying last 90 days
No open-market insider purchases were filed for URGN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every URGN insider filing, plotted on the chart in Gekko.Open URGN in Gekko
NASDAQ: URGN
UroGen Pharma (URGN) Stock Analysis & Forecast
Oct 12 close
$38.28+1.45 (+3.9%)
Gekko Brief
AI summaryOct 12 closeThis week's moves for UroGen Pharma center on analyst sentiment and insider filings rather than new operational news. Marketbeat reports a consensus "Moderate Buy" recommendation with an average price target of $52.38 from ten brokerages, while Jefferies reiterated its Buy rating and a $56.00 price target, citing Q2 2026 revenue growth to $72.5 million alongside a continued net loss. Separately, officer Christopher Degnan filed a Form 144 to sell 2,202 shares valued at approximately $89,621.40 to cover tax withholding tied to vesting RSUs.
URGN closed at $38.28, up 3.9%, sitting between its 50-day average of $43.71 and its 200-day average of $30.42, reflecting a mixed trend. The stock has fallen 9.5% over the past month but remains up 88.8% over six months and 133.1% over the past year. The GekkoIndex reads 70.7, placing the stock in the Buying zone, and the price sits 23.6% below the Gekko Fair Value of $50.08.
Over the next 20 trading days, the key event is the earnings report scheduled for 5 November, 24 days away, falling inside a typical holding window. The prior report on 5 August showed a loss of $0.28 per share against a $0.38 estimate, with a 14.2% reaction. Seasonality from this point has averaged a 11.3% move over five years, with gains in four of them. No insider, Congress, or unusual options activity appears in their respective windows.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
UroGen Pharma price vs fair value
Close $38.28200-day averageGekko Fair Value $50.08
UroGen Pharma quick facts
- Market cap
- $1.87B
- P/E ratio
- —
- Forward P/E
- 36.5
- EPS, TTM
- −$1.97
- Revenue, TTM
- $188.7M
- Profit margin
- -51.7%
- Dividend yield
- —
- Beta
- 1.58
- Volume
- 530,998 avg 963,299
- 1-year return
- +133.1%
- Typical daily move
- ±5.4%
- Typical 20-day move
- ±13.1%
- 50-day average
- $43.71
- 200-day average
- $30.42
- Next earnings
- Nov 5
- Shares outstanding
- 48.88M
UroGen Pharma swing-trade checklist
UroGen Pharma scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $38.28 sits between the 50-day ($43.71) and 200-day ($30.42) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
70.7, Buying
Reading 70.7 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
23.6% below
Price is 23.6% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+11.3% on average
From this point in the calendar, the next 20 trading days averaged +11.3% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
UroGen Pharma stock chart and price history
UroGen Pharma closed at $38.28 on Oct 12, 2026, +133.1% over the past year, inside a 52-week range of $15.86 to $50.81.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −9.5%
- 3 months
- −2.3%
- 6 months
- +88.8%
- 1 year
- +133.1%
The full URGN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open URGN in Gekko
Follow UroGen Pharma through every session
Put URGN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track URGN in GekkoFree for 7 days. No credit card required.
About UroGen Pharma
UroGen Pharma focuses on treatments for cancers of the urinary tract, including bladder and upper tract disease. Its work centers on a proprietary hydrogel technology designed to allow drugs to remain in place for sustained, localized delivery rather than brief exposure. Among its offerings are a generic chemotherapy agent used after surgical removal of bladder tumors, a sustained-release version of that same chemotherapy for non-muscle invasive bladder cancer, and a therapy applied directly within the kidney's collecting system for related tumors.
Beyond its marketed products, UroGen Pharma is advancing several candidates through clinical trials, including two in late-stage testing aimed at low-grade forms of urothelial cancer, and earlier-stage combination therapies targeting high-grade disease. The company works with outside partners on parts of its pipeline, including an arrangement to develop and commercialize certain cancer treatments with another biotechnology firm, and a separate agreement covering development and supply for two of its late-stage candidates.
UroGen Pharma was incorporated in 2004 and is headquartered in Princeton, New Jersey. Its shares are listed on the NASDAQ under the ticker URGN.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- urogen.com
UroGen Pharma GekkoIndex: the smart money zone
UroGen Pharma’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 70.7, in the Buying zone, up 10.6 points over five sessions.
70.7Buying
Up 10.6 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 22 | Not available | |||
| Accumulation | 281 | +1.3% | +3.7% | ||
| Neutral | 323 | +1.9% | +4.2% | ||
| Distribution | 54 | −0.9% | −0.1% | ||
| Selling | 2 | Too few readings yet | |||
Average URGN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.1% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the URGN price, zone by zone.Track URGN in Gekko
Is UroGen Pharma stock overvalued? Gekko Fair Value
UroGen Pharma trades 23.6% below Gekko Fair Value of $50.08, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what UroGen Pharma shares are worth, recalculated every trading day.
$50.08
Gekko Fair Value, Oct 10, 2026
23.6% Undervalued
At the end of Aug 2026 the price was 19.7% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open URGN in Gekko
UroGen Pharma insider and Congress trading
No open-market insider purchases were filed for UroGen Pharma, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in URGN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for URGN, plotted on the chart in Gekko.Open URGN in Gekko
Buybacks
UroGen Pharma has been buying back its own shares.
- Bought back, quarter ended Dec 31, 2021
- $15K
- As a share of market cap
- 0.00%
From company filings.
UroGen Pharma earnings: next date and track record
UroGen Pharma reports on Nov 5, 2026 (24 days away), and beat the EPS estimate in 2 of its last 8 reports.
Next earnings report
Nov 5, 2026
24 days away
- EPS estimate
- $0.10
- Revenue estimate
- $90.58M
2 of 8reports beat the EPS estimate
±10.5%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- UroGen's Q2 2026 showed strong momentum with ZUSDURI generating $50.4M in net product revenue, a 73% sequential increase from Q1. Activated accounts grew to 1,444 from 972, unique prescribers doubled to 452, and repeat prescribers reached 45% of writers. Community practice adoption reached 55% of utilization, with 95%+ covered lives having open access and no material reimbursement barriers.
- Guidance
- Management reiterated 2026 financial guidance and expects continued ZUSDURI growth through the balance of the year. Company targets improving enrollment-to-treatment conversion to 2-3 weeks, consistent with JELMYTO benchmarks, with community practices expected to drive long-term growth given ~70% addressable market concentration there.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | −$0.28 est −$0.38 | $72.46M est $63.55M | +14.2% |
| May 6, 2026 | −$0.47 est −$0.46 | $50.96M est $44.83M | +11.6% |
| Mar 2, 2026 | −$0.53 est −$0.48 | $37.84M est $39.91M | −13.3% |
| Nov 6, 2025 | −$0.69 est −$0.68 | $27.48M est $40.13M | +20.4% |
| Aug 7, 2025 | −$1.05 est −$0.83 | $24.22M est $33.57M | −11.3% |
| May 12, 2025 | −$0.92 est −$0.79 | $20.25M est $23.26M | −2.3% |
| Mar 10, 2025 | −$0.80 est −$0.72 | $24.57M est $23.34M | +10.2% |
| Nov 6, 2024 | −$0.55 est −$0.82 | $25.20M est $26.13M | −0.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
UroGen Pharma stock forecast and analyst price targets
Analysts’ average 12-month price target for UroGen Pharma is $60.00, +56.7% from the last close, from 5 firms rating the stock in the last 90 days.
$60.00consensus 12-month target, +56.7% from the last close
Now $38.28Avg $60.00
Low $48High $75
Each firm’s latest rating in the last 90 days: 5 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 20 | H.C. Wainwright | $75 | +95.9% |
| Aug 11 | H.C. Wainwright | $75 | +95.9% |
| Aug 6 | Oppenheimer | $60 | +56.7% |
| Aug 6 | H.C. Wainwright | $75 | +95.9% |
| Aug 5 | Goldman Sachs | $48 | +25.4% |
+11.3%average move over the next 20 trading days in the last 5 years
±5.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
UroGen Pharma seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, UroGen Pharma averaged +11.3% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.9% | 4 of 5 |
| Next 10 trading days | +1.9% | 4 of 5 |
| Next 15 trading days | +6.4% | 4 of 5 |
| Next 20 trading days | +11.3% | 4 of 5 |
| Next 30 trading days | −1.3% | 1 of 5 |
For scale, URGN’s typical 20-trading-day move in either direction is about 13.1%.
UroGen Pharma market cap and key statistics
UroGen Pharma’s market cap is $1.87B and revenue of $188.7M over the last twelve months.
Valuation
- Market cap
- $1.87B
- Forward P/E
- 36.5
- EPS, TTM
- −$1.97
- Gekko Fair Value
- $50.08
Trading
- Volume
- 530,998
- Avg volume, 20 days
- 963,299
- 52-week high
- $50.81
- 52-week low
- $15.86
- Shares outstanding
- 48.88M
Financials
- Revenue, TTM
- $188.7M
- Profit margin
- -51.7%
- Return on equity
- -1481%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.58
- Typical daily move
- ±5.4%
- Typical 20-day move
- ±13.1%
UroGen Pharma stock news this week
Coverage of UroGen Pharma this week reads neutral: 3 positive, 9 neutral and 0 negative headlines.
- Urogen Pharma (NASDAQ:URGN) Stock Has Consensus Price Target of $52.38 According to AnalystsDefense World, Oct 12
- UroGen Pharma CFO Chris Degnan sells $80,791 in shares By Investing.comInvesting.com Nigeria, Oct 9
- Form 4 Urogen Pharma Ltd For: 9 October By Investing.comInvesting.com Nigeria, Oct 9
- Form 4 Urogen Pharma Ltd For: 9 OctoberInvesting.com India, Oct 9
- Form 144 UroGen Pharma Ltd. For: 9 October By Investing.comInvesting.com Nigeria, Oct 9
- Form 144 UroGen Pharma Ltd. Filed by: Degnan ChrisStreetInsider, Oct 9
UroGen Pharma peers
UroGen Pharma’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
UroGen Pharma stock FAQ
What is UroGen Pharma’s market cap?
UroGen Pharma’s market cap is $1.87B at the Oct 12, 2026 close of $38.28, with 48.88M shares outstanding.
What is the UroGen Pharma stock forecast?
The consensus analyst 12-month price target for UroGen Pharma is $60.00, +56.7% from the last close. Of the 5 firms that rated the stock in the last 90 days, 4 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is UroGen Pharma stock overvalued or undervalued?
On Gekko’s estimate UroGen Pharma is undervalued: the Oct 12, 2026 close of $38.28 is 23.6% below Gekko Fair Value of $50.08. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does UroGen Pharma report earnings next?
UroGen Pharma is expected to report on Nov 5, 2026 (24 days away). Analysts expect earnings of $0.10 per share on revenue of $90.58M. UroGen Pharma beat the earnings estimate in 2 of its last 8 reports, moving 10.5% on average across the report.
What is UroGen Pharma’s 52-week high and low?
UroGen Pharma’s 52-week high is $50.81 and its 52-week low is $15.86; it closed at $38.28 on Oct 12, 2026, +133.1% over the past year.
Is UroGen Pharma stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (gekkoindex, fair value and seasonality), 1 as mixed (trend) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See UroGen Pharma the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.